DBV Technologies to Participate in Upcoming Investor Conference
11/22/2022 - 04:30 PM
Montrouge, France, November 22, 2022
DBV Technologies t o Participate i n Upcoming Investor Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 5th Annual Evercore ISI HealthCONx Conference taking place Nov. 29 – Dec. 1, 2022. Daniel Tassé, Chief Executive Officer, will participate in a Fireside Chat session on Wednesday, Nov. 30, at 8 a.m. ET, as well as one-on-one investor meetings throughout the day.
A live webcast of the fireside chat will be available on the Investors & Media section of the Company’s website: https://wsw.com/webcast/evercore29/dbvt/2371680 .
A replay will also be available on DBV Technologies’ website for 90 days after the event.
About DBV Technologies
Investor Contact anne.pollak@dbv-technologies.com
Media Contact angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV Technologies.
DBVT Rankings
#3835 Ranked by Stock Gains
DBVT Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
France
City
Montrouge
About DBVT
dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and
